Eli Lilly (NYSE:LLY) and Incyte (NASDAQ:INCY) are set to seek a label expansion for their JAK inhibitor baricitinib, marketed ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance ...

Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take ...

Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on ...

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

The Hollywood star sat down with Newsweek to discuss his next big project: upping enrollment in clinical trials.

Stream Connecticut News for free, 24/7, wherever you are. The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific Sessions meeting ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A ...

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...